1. Attar, M., Brassard, J.A., Kim, A.S., Matsumoto, S., Ramos, M. and Vangyi, C. (2013): Safety evaluation of ocular drugs. In A Comprehensive Guide to Toxicology in Preclinical Drug Development (Faqi, A.S. ed.), pp.567-617, Elsevier, Amsterdam.
2. Chrai, S.S., Makoid, M.C., Eriksen, S.P. and Robinson, J.R. (1974): Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J. Pharm. Sci., 63, 333-338.
3. CPMP/SWP (2001): Note for guidance on non-clinical local tolerance testing of medical products. Committee for proprietary medical products (CPMP) / Safety Working Party (SWP).
4. FDA/CDER (2008): Guidance for industry and review staff. Nonclinical safety Evaluation of reformulated drug products and products intended for administration by an alternate route (Draft guidance). Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER).
5. Fraunfelder, F.T. (2015a): Ocular drug delivery and toxicology. In Drug-Induced Clinical Ocular Side Effects (Fraunfelder, F.T., Fraunfelder, F.W. and Chambers, W.A. eds.), pp.9-14, Saunders Elsevier.